News

EPAM Systems: Acquisition Strategies and Market Insights

EPAM Systems: Acquisition Strategies and Market Insights

EPAM Systems Maintains Hold Rating Amid Acquisition Plans

EPAM Systems (NYSE: EPAM) has been in the spotlight following TD Cowen's recent decision to uphold a Hold rating with a steady price target of $200. This decision aligns with the announcement of EPAM's acquisition of First Derivative, a company known for its IT and knowledge process outsourcing services, particularly in the capital markets sector. First Derivative brings to the table a workforce exceeding 1,800 employees and recorded revenues of £170 million for the last fiscal year.

Financial Metrics and Acquisition Impact

While First Derivative's revenue reflects an 8% decrease year-over-year, with an adjusted EBITDA margin of just 11%, EPAM anticipates that the acquisition could contribute an estimated five percentage points to its annualized revenue growth. Nevertheless, there's cautious optimism due to the inherently lower margins associated with First Derivative's diverse service offerings. TD Cowen's evaluation estimates an enterprise value to sales (EV/Sales) ratio of about 1.4 and an EV/EBITDA ratio of close to 13. The potential effects on EPAM's earnings per share (EPS) for 2025 are expected to be neutral, keeping analysts and investors on alert regarding future profitability.

Strategic Acquisitions and Market Position

EPAM’s recent strategic endeavors, including the acquisition of NEORIS, a well-regarded global tech consultancy, have drawn significant attention. Despite concerns regarding the integration of the two companies and the broader market implications, firms like Piper Sandler and Mizuho have remained optimistic. Piper Sandler has upgraded its rating to Overweight, while Mizuho has maintained an Outperform rating, acknowledging EPAM's potential for growth driven by these acquisitions.

Responding to Geopolitical Challenges

However, challenges remain. Deutsche Bank's initiation of coverage with a Hold rating stems from operational hurdles EPAM has faced over recent years, exacerbated by geopolitical unrest affecting market stability. Analysts are closely watching how EPAM navigates these turbulent waters, considering the potential impacts on its growth trajectory.

Recent Performance and Future Outlook

Financial forecasts look tentative as well, with EPAM Systems revising its 2024 organic constant currency revenue expectations downward. Mizuho has adjusted its stock price target from $258 to $245, but they continue to express confidence in the company's long-term viability. In light of the growing potential of artificial intelligence, Jefferies has boosted its stock rating from Hold to Buy, raising its price target to $237, indicating a favorable outlook amongst some analysts. Conversely, Goldman Sachs has initiated coverage at a Neutral rating, also maintaining a price target of $200.

Insights from Recent Market Data

Recent insights from market data reveal critical details surrounding EPAM Systems' market position. The company's market capitalization is currently at $11.01 billion with a P/E ratio of 27.29. This indicates how the market evaluates EPAM, suggesting stability despite the challenges faced in the IT services sector. A positive indicator is the fact that EPAM has a robust cash position, holding more cash than debt, which positions the company favorably as it integrates First Derivative and adapts to market shifts.

Revenue and Profitability Analysis

Over the last twelve months up until Q2 2024, EPAM reported revenues amounting to $4.62 billion, managing a slight contraction of 4.5% in revenue growth. This aligns with the anticipated revenue enhancements post-acquisition of First Derivative. Furthermore, EPAM has maintained profitability, achieving a gross profit margin of 30.11% and an operating income margin of 11.63%. These key metrics will require close monitoring as the company expands its service scope by incorporating First Derivative's offerings.

Frequently Asked Questions

What is TD Cowen's rating for EPAM Systems?

TD Cowen has maintained a Hold rating and a price target of $200 for EPAM Systems.

How much revenue did First Derivative report?

First Derivative reported revenues of £170 million for the fiscal year ending in February 2024.

What are the anticipated effects of the acquisition on EPAM's revenue growth?

The acquisition is expected to contribute approximately five percentage points to EPAM's annualized revenue growth.

How has EPAM Systems' stock rating changed recently?

Jefferies upgraded EPAM's stock rating from Hold to Buy, raising the price target to $237.

What is EPAM Systems’ gross profit margin?

EPAM Systems reported a gross profit margin of 30.11% over the last twelve months.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Amy Johnson Steps Up as GDIT President Amid Shifts

Updated Category News Views 24

A New Chapter for GDIT with a Veteran Leader Big shoes to fill? Nah, more like Amy Johnson was made for these shoes. Stepping up as president of General Dynamics Information Technology (GDIT) on November 3, she’s got 27 years of experience under her belt, all from General Dynamics' own backyard. This ain't her first rodeo. From tightrope-walking the perils of defense...

Continue Reading
Steady Income Boosts FHLBank Boston's Growth Q3 2026

Updated Category News Views 4

The Federal Home Loan Bank of Boston dropped their third-quarter results for 2026 like a hot smokestack, and let me tell you, it's a mixed bag of cautious optimism and steady progression. It's essentially proof that slow and steady might just win the race—or at least keep you in the running. Stable and Steady Headway Taking a peek under the hood, FHLBank Boston made a...

Continue Reading
Meissner's Big Move in Athens Expands Irradiation Capacity

Updated Category News Views 6

An Expansion That Matters Take a deep breath, folks, because what Meissner's pulling off in Athens ain't just small potatoes. The corporation's got a new X-ray irradiation facility under its belt, and they've taken the shovel to the ground for Phase 2 of their manufacturing campus. In an industry where being first is everything, doubling down on infrastructure proves...

Continue Reading
Dott's Q3 2026: Micromobility Growth Soars High

Updated Category News Views 7

Riding the Wave of Profit in Micromobility Sometimes all you need is a quick jolt of genius to turn the wheels of fortune. Dott seems to have hit that sweet spot in Q3 of 2026. Deploying 45,000 new vehicles wasn’t just a logistical feat; it was a calculated bet that paid off handsomely, bolstering their business to soaring heights. Performance that Packs a Punch The Q3...

Continue Reading
Hansa's Idefirix Shows Promise for Kidney Transplants

Updated Category News Views 4

Compelling Progress from Hansa Biopharma Y'know, navigating through the biotech jungle isn't for the faint-hearted. Hansa Biopharma's recent results with Idefirix could just be the beacon of hope for patients struggling on transplant lists. Announced at the ASN Kidney Week—a name that's got weight, by the way—these findings aren't just filling space. They're promising...

Continue Reading
Think Together Marks 20 Years of ASES Impact in CA

Updated Category News Views 40

Hands-on Learning: California's Bright Future Starts Here Who's ever thought a schoolyard's the same after three? Let me tell you, in California, it's staying alive and kicking, thanks to Think Together's whirlwind of celebrations for the After School Education and Safety (ASES) program. We're talking 450 schoolyard shindigs highlighting not just how far expanded learning...

Continue Reading
John Wong's Decade as Estate Planning Specialist

Updated Category News Views 29

One man's legacy isn’t built overnight, especially not in estate planning. And John L. Wong's decade of being a certified specialist by the State Bar of California tells a story of perseverance and grit. Now, at the helm of Modern Wealth Law in Irvine, California, Wong is a name that echoes through the halls of estate planning law with authority and respect. Creating...

Continue Reading
Lincoln Educational Faces Investor Lawsuit Over Revenue Drop

Updated Category News Views 46

Investors Face Rough Waters Okay, let’s dive into this latest mess at Lincoln Educational Services Corp. (NASDAQ:LINC). Things aren't smelling too rosy over at their headquarters. If you've got shares here, you’ll know what I mean. Back in early May, the folks running Lincoln threw a garden party talking up a 19.5% growth in student starts. Who wouldn’t get behind...

Continue Reading
Howard Hughes Joins S&P SmallCap 600, Arcosa Out

Updated Category News Views 25

Shakeup in the S&P SmallCap 600 It’s one of those days where something shifts in the market landscape—Howard Hughes Holdings Inc. (NYSE: HHH) is swaggering into the S&P SmallCap 600. Kicking off on October 28, it's got quite the entrance lined up. On the other end, Arcosa Inc. (NYSE: ACA) is making a hasty exit after getting scooped up by CRH plc (NYSE: CRH). For...

Continue Reading
Autoliv Sees Mixed Q3 2026 Amid Global Challenges

Updated Category News Views 6

An Uneven Road: Autoliv's Q3 2026 Chronicle You'd think by now everyone in the automotive game would have mastered the art of the pivot. Well, Autoliv seems to have gotten the memo for Q3 2026. Sales dipped slightly, yet their moves in Asia hint at a calculated gambit in a rough global landscape. Digging into the Numbers The financials were a mixed bag. Net sales huddled...

Continue Reading

Top 5 Most Recently Viewed Articles

Rubico Inc. Secures Time Charter Extensions to Enhance Revenue

Updated Category News Views 140

Rubico Inc. Expands Financial Outlook with Charter Extensions Rubico Inc. has made headlines recently as it announces the extension of time charters for both of its modern tanker vessels, supporting its steady growth in the shipping industry. Known for its eco-friendly, fuel-efficient tanker vessels, this move reflects the company's commitment to optimizing its...

Continue Reading
Exploring High-Yield Dividend Stocks in the Industrials Sector

Updated Category News Views 187

Investing in Dividend-Yielding Stocks During turbulent times in the financial markets, investors often seek refuge in dividend-yielding stocks. These stocks are typically from companies with strong free cash flows that reward their shareholders. In particular, high-yield dividend stocks can be an attractive option for those looking to generate income from their...

Continue Reading
Foventa Therapeutics: Spotlight on Diabetic Eye Treatment

Updated Category News Views 25

Foventa's Shift: From Science to Clinical Focus Well, isn't this a twist of fate? Exonate, the company that once thrived on cutting-edge science, is shedding its old skin and stepping into a new spotlight as Foventa Therapeutics. The old moniker is in the rearview, and now they're pledging to tackle non-proliferative diabetic retinopathy (NPDR) with a fresh angle—a...

Continue Reading
Elevating Patient Care: Viz.ai and Illuminate Unite Forces

Updated Category News Views 180

Innovative Partnership Between Viz.ai and Illuminate In a significant stride for patient care, Viz.ai has announced a collaborative expansion with Illuminate, a company renowned for its advancements in AI and natural language processing. This partnership aims to revolutionize the identification and monitoring of patients with cerebral aneurysms, facilitating timely...

Continue Reading
Trilogy Metals Shares Fiscal Insights and Project Developments

Updated Category News Views 328

Trilogy Metals Shares Fiscal Insights and Project Developments Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ), a notable player in metal exploration, recently announced its financial results for the third quarter ending August 31, 2025. The latest updates detail the company's fiscal health, progressive projects, and future outlook, revealing a net loss of $1.7...

Continue Reading